k8·凯发天生赢家·一触即发(中国区)官方网站

Ms. Li’s experience includes providing legal services for:

• Hong Kong Asia Medical Group (a leading brand of cardiovascular medical care in Asia) in its $400 million Series D financing, which is the largest PE transaction of the year in China’s medical service field.
• ImmuneOnco (anti-tumor biotechnology) in its nearly $100 million cross-round financing.
• JLSemi (network communication chip design) in completing multiple rounds of equity financing with a total of more than $100 million and cross-border investment projects, as well as providing ongoing legal advisory services.
• Northern Light Venture Capital in its early round of VC investment in a number of high-end manufacturing and new material companies (such as AROMEM).
• Equity financings of chip startups such as AM Microelectronics and GLS, and serves as their long-term legal advisor.
• Huagai Capital's lead investment in MindRank (AI pharmaceuticals) in a Series A investment exceeding RMB 100 million.
• Linkzill (biological chips) in its early-stage financing and serves as its long-term legal advisor.
• Provided LDD and negotiation of transaction documents for PE investment projects of investment firms such as Huagai Capital, Shanjin Capital, Haoyue Capital, Lake Bleu Capital, and Northern Light Venture Capital.
• NewMed(heart valve replacement) in its Series C financing exceeding $100 million.
• Stphibio (Car-T cell therapy) in its Series A financing of several hundred million RMB from renowned investors including Shenzhen Venture Capital and VMS.
• GSR Ventures' dollar fund in its early-stage investment in Cloudpick (AI unmanned technology).
• TiLiGH (multi-omics oncology early screening) in multiple rounds of financing and serves as its long-term legal advisor.
• YF Capital's participation in Nanos Medical's (ENT diagnostic and treatment platform) Series D investment.
• Huagai Capital's lead investment in NK Cell Tech (NK cell therapy) in a Series A investment exceeding RMB 100 million.
• WeMed (high-end interventional diagnostic and therapeutic equipment) in its Series C+ financing of RMB 100 million led by Hillhouse Capital.
• Lake Bleu Capital's participation in late-stage equity investment.

Ms. Li’s experience includes providing legal services for:

• Silver Lake (a Well-known US-based PE firm) in its reorganization and divestiture of China's largest internet advertising giant, Allyes Group, and in the subsequent sale to multiple buyers for several hundred million RMB.
• ABclonal (antibody and molecular enzyme reagents) in its acquisition of 100% equity in Yurogen Biosystems (US biotech company).
• Sinopharm National Pharmacy in its RMB 2.77 billion capital increase to introduce international strategic investor Walgreens Boots Alliance, which was the largest cross-border joint venture transaction of the year in China's pharmaceutical distribution sector.
• CTI Group (a leading institution in domestic testing) in its acquisition of FengXue Network Security, a company specializing in cybersecurity level evaluation.
• Celepixel in its sale of the controlling stake to a subsidiary of OMNIVISION (a Chinese listed company).
• Yum China (the parent company of KFC) in its acquisition of the controlling stake in a Chinese restaurant brand, Huangjihuang Group.
• Structure adjustment and equity transfer transactions carried out before the financing of Stphibio (Car-T cell therapy).
• Potential restructuring and financing transactions by OPNOUS (high-end analog chips and smart optoelectronic sensing chips).
• Cowealth (listed on mainland and Taiwan) regarding the design and setup of equity structure for the implementation of an AI application software project.
• Provided lawyer placement support for ClinChoice (a CRO service provider) regarding its structural adjustments and perennial legal services.
• GenFleet (tumor and immune drug development company) on significant managerial decisions.

Ms. Li’s experience includes providing legal services for:

• Leads Biolabs in its global licensing and collaboration agreement with BeiGene for the anti-LAG-3 antibody LBL-007, which exceeded US 700 million. In this transaction, Leads Biolabs retained its interests in China and received a down payment of US $30 million; BeiGene was licensed exclusively for commercialization outside of China. Upon reaching clinical development, regulatory approval and sales milestones, Leads Biolabs will be entitled to receive up to $742 million in gross revenue and double-digit tiered sales royalties in licensed territories.
• WuXi AppTec’s Southeast Asia Healthcare Fund (SEA) in its acquisition of IP licensing of two assets.
• N1 Life Inc. (a US startup established by a Stanford PhD) in its IP license and joint venture with Accuredit.
• IP licensing and commercialization transaction between Transcenta (a HK listed Company) and Alebund (a startup incubated by Lilly Asia Ventures), as well as their joint venture for research and development.
• Leads Biolabs and BioneCure reached cooperation on the joint development project of ADC bioinnovative drugs.
• IP licensing transaction between Stphibio and Livzon.
• Bio-combo collaborates with its customers on ADC product development.